Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Urinary Bladder Neoplasms. Found 22 abstracts

no pagination
Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O. 2019 Mar;17(3):176-83.
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2018 Dec;4(6):937-45.   PMCID: PMC5626651
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240-67.
Waingankar N, Mallin K, Smaldone M, Egleston BL, Higgins A, Winchester DP, Uzzo RG, Kutikov A. Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy. BJU international. 2017 Aug;120(2):239-45.
Cahn DB, Ristau BT, Ghiraldi EM, Churilla TM, Geynisman DM, Horwitz EM, Uzzo RG, Smaldone MC. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016 Oct;96:54-61.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213-24.   PMCID: PMC5379654
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Fatima N, Canter DJ, Carthon BC, Kucuk O, Master VA, Nieh PT, Ogan K, Osunkoya AO. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. The Canadian journal of urology. 2015 Jun;22(3):7783-7.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Norberg SM, Oros M, Manucha V, Eun D, Bilusic M. Loss of e-cadherin and retinoblastoma genes in a case of urothelial carcinoma with scrotal metastasis. The Canadian journal of urology. 2015 Apr;22(2):7755-7.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901.   PMCID: PMC4050203
Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye [Letter]. J Clin Oncol. 2014 Dec 20;32(36):4171-2.
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol. 2014 Nov;192(5):1349-54.   PMCID: PMC4422495
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug;32(6):826-32.   PMCID: PMC4687398
Canter D, Simhan J, Smaldone MC, Lebed B, Tokar JL, Wu KN, Uzzo RG, Gustafson KS, Patchefsky AS, Plimack ER, Hoffman JP, Kutikov A. Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreas. Urology. 2012 Feb;79(2):e9-10.   PMCID: not NIH funded
Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncol Rep. 2012 May;27(5):1400-6.
Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU international. 2011 Jan;107(1):58-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Urinary Bladder Neoplasms

Urinary Bladder Neoplasms pathology therapeutic use Female Male Transitional Cell Carcinoma methods drug therapy Aged Neoadjuvant Therapy therapy 80 and over Aged Middle Aged Cystectomy Neoplasm Invasiveness mortality Antineoplastic Agents Neoplasm Staging Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Retrospective Studies Prognosis Combined Modality Therapy Adjuvant Chemotherapy Adult Cisplatin surgery Bladder cancer statistics & numerical data Neoplasm Metastasis Survival Rate secondary Disease-Free Survival Doxorubicin cystectomy bladder cancer Phase II Clinical Trials as Topic Methotrexate diagnosis Protective Agents Smooth Muscle administration & dosage Vinblastine chemically induced Proportional Hazards Models Prospective Studies genetics Granulocyte Colony-Stimulating Factor analysis Urothelial carcinoma chemistry Urothelium Intestinal Neoplasms Robotic Surgical Procedures Cisplatin sensitivity immunotherapy Perioperative chemotherapy Cyclooxygenase 2 Inhibitors Tetrahydronaphthalenes muscle invasion Genetic Markers checkpoint blockade metabolism health care Non-muscle-invasive Propensity Score Mutation Oncologists Research Design Quality of Health Care Rb1 Fatigue Skin Neoplasms drug Pancreatic Ducts Chemoradiotherapy epidemiology AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb Clinical Competence Gene Expression Profiling Rats Multivariate Analysis Ctla-4 pd-1 Review hospitals Cell Cycle Checkpoints Inbred F344 Rats High-Volume Hospitals DNA Repair Local Neoplasm Recurrence quality indicators Filgrastim Carcinoma CTLA-4 Antigen pd-l1 Salvage Therapy Pancreatic Neoplasms B7-H1 Antigen Pd-1 dosage Tumor Biomarkers Animal Disease Models Registries Young Adult Follow-Up Studies Muscle Neoplasms Randomized Controlled Trials as Topic Hospitals gemcitabine plus cisplatin Retinoblastoma Genes Sprague-Dawley Rats etiology Robot-assisted surgery ctla-4 Non-Steroidal Anti-Inflammatory Agents Preclinical Drug Evaluation drug effects doxorubicin Micropapillary Colonic Neoplasms disclosed No writing assistance was utilized in the production of this Radiotherapy urothelial carcinoma The authors have no other relevant affiliations or financial involvement with any Survey Drug Therapy Sulfonamides Atm Lymph Nodes institutionally directed clinical trial support from Horizon Pharma ER Plimack Perioperative Care Adolescent Recombinant Proteins Fancc regionalization neoadjuvant Muscle-invasive disease outcomes Protein Kinase Inhibitors Margins of Excision immunology Knockout Mice Treatment Cadherins Eli Lilly has served on advisory boards and as consultant for Genentech Biomarkers Anticarcinogenic Agents Pyrazoles Cisplatin resistance
Last updated on Friday, December 06, 2019